Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours (LET-PT)

10 novembre 2026 mis à jour par: Universitaire Ziekenhuizen KU Leuven

Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study

The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.

Aperçu de l'étude

Description détaillée

In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.

Secondary objectives are:

  • To gain further insight into the feasibility of an LET-based treatment planning method in primary brain tumours.
  • To assess additional side effects after PT for primary brain tumours.
  • To investigate the response of primary brain tumours after PT.

Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Patients diagnosed with primary brain tumours including, but not limited to:

    1. Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted
    2. Ependymal tumours
    3. Tumours of the sellar region including, but not limited to, craniopharyngioma
    4. Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours
    5. Meningioma
    6. Primary neuroectodermal tumours
    7. Germ cell tumours
    8. Choroid plexus tumours
    9. Pineal tumours
  2. Both adults and children are eligible for inclusion

  3. Referred to PARTICLE for proton therapy treatment

  4. Treatment with PT approved and reimbursed by RIZIV/INAMI

  5. Ability of patient and/or parents or legal guardian to sign informed consent

Exclusion Criteria:

  1. Mixed photon-proton planning
  2. Re-irradiation
  3. Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: LET-based evaluation in treatment planning

Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.

Autres noms:
  • Protonthérapie
  • LET-based treatment evaluation
  • LET-based treatment planning
  • variable RBE-based treatment evaluation
  • variable RBE-based treatment planning

MRI assessments according to routine follow-up for TRIA and response assessment.

Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module.

Evaluating the incidence of CNS toxicities using the CTCAE v5.0

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
Délai: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.

TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0.

Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Treatment planning feasibility: number of plan iterations.
Délai: Baseline (during treatment planning).

Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow.

Baseline (during treatment planning).
Treatment planning feasibility: number of plans requiring LET-based replanning.
Délai: Baseline (during treatment planning).

Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan.

Baseline (during treatment planning).
Treatment planning feasibility: planning effort
Délai: Baseline (once before and once after LET-based replanning).

Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome).

Baseline (once before and once after LET-based replanning).
CNS toxicities
Délai: Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.

Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome.

Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Délai: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome).

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Délai: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in adults (aged >25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome).

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Délai: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life.

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Response assessment
Délai: At 6 and 12 months after proton therapy.

Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria.

At 6 and 12 months after proton therapy.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Délai: Baseline (after treatment planning).

Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Délai: Baseline (after treatment planning).

Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Délai: Baseline (after treatment planning).

Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Délai: Baseline (after treatment planning).

Comparing target coverage, reported as [CTV D98%] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 avril 2028

Achèvement de l'étude (Estimé)

1 avril 2029

Dates d'inscription aux études

Première soumission

21 octobre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner